On December 27 & 28, 2016, Faruqi & Faruqi, LLP filed several cases against generic drug manufacturers for allegedly conspiring to raise the prices of generic divalproex ER, desonide, pravastatin, econazole, fluocinonide, levothyroxine, propranolol, and clobetasol. The firm represents classes of direct purchasers of the generic drugs and is seeking an award of triple damages under the Clayton Act. The cases were filed in federal court in Philadelphia. They are as follows: Case Nos. 2:16-cv-06645; 2:16-cv-06662; 2:16-cv-06644; 2:16-cv-06638; 2:16-cv-06639; 2:16-cv-06671; 2:16-cv-06672; 2:16-cv-06644. Collectively, the generic companies named are Dr. Reddy’s, Impax, Mylan, Par, Zydus, Actavis, Fougera, Perrigo, Sandoz, Sun, Taro, Apotex, Glenmark, Lupin, Teva, Teligent, Lannett, Endo, Heritage, Breckenridge, Upsher-Smith, Hi-Tech, and Wockhardt.
The cases follow a series of governmental investigations at the state and federal level, which led to two criminal indictments and a state attorneys general action. Faruqi & Faruqi also serves as counsel for the class in In re Generic Digoxin and Doxycycline Antitrust Litigation, Case No. 2:16-md-02724, an action previously filed against generic drug manufacturers in Pennsylvania federal court.